Adults with difficult access
Dehydration, chronic illness, oncology, obesity, and repeated cannulation can all make veins hard to find and easy to miss. Clear imaging gives the clinician a better read before the first attempt.
Forest Bloom · Medtech
Find the vein. First time.
VeinMate Assist is an AI-guided, clinician-executed device for IV cannulation and blood sampling. It images the vein, identifies the optimal insertion point, and puts that guidance in the clinician's hands — where the decision belongs.
Design patent granted, Govt. of India
CDSCO Class B pathway
Built for Indian clinical settings
The problem
Every day, millions of first attempts fail.
Peripheral IV access is the most common invasive procedure in medicine — and one of the least reliable. First-attempt failure is routine, repeat sticks are painful and costly, and difficult-access patients suffer most. Behind every missed vein sits wasted clinician time, higher infection risk, and a worse experience for the person on the table.
~40%
of first IV attempts in adults miss on the first try.
~64%
of first attempts in children miss on the first try.
~2B
vascular access procedures performed worldwide each year.
Statistics reflect widely reported ranges in clinical literature; see the reference note in the footer.
How it works
Guidance to the clinician — not around them.
VeinMate Assist keeps the trained clinician in control of the procedure. The device does the seeing; the clinician does the deciding and the doing.
1
Image
Near-infrared imaging and ultrasound depth sensing map the vein and its depth.
2
Guide
On-device AI identifies the optimal insertion point and presents it clearly.
3
Clinician acts
The trained clinician confirms the target and performs the access.
4
Record
Every session is logged for audit, quality review, and analytics.
Who it's for
Built for the sticks that go wrong most often.
Some patients and settings make vascular access far harder than a textbook forearm. VeinMate Assist is designed to support the clinician exactly where the first attempt is most likely to miss.
Paediatric patients
Small, fragile veins and a low tolerance for repeat sticks make children among the hardest cases in the ward. Guidance is designed to help the clinician get it right gently, and sooner.
High-volume diagnostic labs
Phlebotomy teams draw blood all day, every day. Consistent, repeatable guidance is intended to support quality and confidence across a heavy caseload.
It is also intended for emergency and ward settings where speed matters and there is little room for a second try.
- Emergency departments, where fast, reliable access can shape the next decision.
- Inpatient wards managing repeat cannulation over a stay.
- Outpatient and day-care units running steady sampling volume.
These describe where the device is intended to help, not a claim of outcomes in any group. Suitability is always the clinician's judgement.
Guidance, not autonomy
The device sees. The clinician decides.
VeinMate Assist is AI-guided and clinician-executed. That distinction is not marketing — it is how the product is designed and how it stays grounded on its regulatory pathway.
What the device does
Images the vein with near-infrared and ultrasound, guides the clinician to an optimal insertion point, and records the session for audit and quality review. It never inserts, punctures, or retracts on its own.
What the clinician always does
Confirms the target, performs the access, and stays fully accountable for the procedure. The trained clinician remains in command from start to finish — the device is there to inform that decision, not to make it.
“We are not taking the clinician out of the loop. We are giving them a clearer picture before the first attempt — and leaving every decision, and every insertion, exactly where it belongs.”
— Forest Bloom
Why VeinMate Assist
Precision you can stand behind.
Fewer sticks, less pain
Better first-attempt guidance means fewer repeat attempts — for every patient, and especially for children and difficult-access cases.
Clinician-first by design
No autonomy claims, no black box in the loop. The clinician stays accountable and in command — which also keeps the regulatory pathway grounded.
Built for the real world
Production-grade components, a single-use guide cartridge, and a workflow designed around how clinical teams actually work.
Designed for equity
Guidance that shouldn't depend on skin tone.
Infrared vein-finding can work well on some patients and poorly on others. Veins that show easily under infrared on lighter skin can be far harder to read on darker skin — which means the patients who most need reliable access can be the ones a tool serves worst.
VeinMate Assist is being designed so that imaging and guidance are intended to work across skin tones, not just those that image easily. Equity is treated as a design requirement, not an afterthought.
This describes a design goal under validation, not a proven performance claim in any population.
Frequently asked
Straight answers to the honest questions.
Does the device insert the needle?
No. The trained clinician performs every access. VeinMate Assist images the vein and guides the clinician to an optimal insertion point — it never inserts, punctures, or retracts on its own.
How does it connect?
Over its own secure Wi-Fi link. The device is designed to operate on a dedicated wireless connection rather than depend on shared hospital networking.
Is it approved for clinical use?
No. VeinMate Assist is an investigational device in development on a CDSCO Class B pathway. It is not approved for sale or clinical use.
What are the performance numbers?
Any figures discussed in briefings are engineering targets under validation — not published clinical results. We are deliberately careful not to present targets as proven outcomes.
Where is Forest Bloom based?
Forest Bloom is based in the Chandigarh region of India, building VeinMate Assist for Indian clinical settings.
Partner with us
We're building the assist clinicians actually want.
Forest Bloom is raising and partnering to move VeinMate Assist from working prototype to clinical pilots. If you're an investor, a hospital, or a lab, we'd like to talk.
Request a briefing